Generic competition · all medicines · read 12 November 2026

Is there a generic of Verapamil Hydrochloride, and who makes it?

Verapamil Hydrochloride appears in 5 dosage-form groups in the FDA Orange Book as of 12 November 2026, with 19 generic makers listed as marketed across them. Where both are dated, the first generic approval came between 1.6 and 8.9 years after the first brand approval. This is the Orange Book's listing, not a forecast.

Method designed and maintained by Vincent Wesley Couey (ORCID 0009-0005-6869-308X). Data compiled automatically from the Orange Book data files, downloaded 12 November 2026. How these pages are made

Not medical advice. This page reports what the FDA's Orange Book lists, not what a pharmacy has in stock, what anything costs, or whether a generic is right for you. Ask your pharmacist or prescriber about your own medicine.
Verapamil Hydrochloride5 dosage-form groups in the Orange Book
19generic makers listed
  1. Verapamil Hydrochloride appears in 5 dosage-form groups in the FDA Orange Book as of 12 November 2026, with 19 generic makers listed as marketed across them.
  2. Where both are dated, the first generic approval came between 1.6 and 8.9 years after the first brand approval.
  3. Patents and exclusivities are shown as listed by the application holder; the Orange Book does not rule on them, and a listed patent is not a statement that a generic is blocked. This says nothing about price, supply or quality.

Tablet, Oral

One to three generic makers listed

Every brand product here is listed as discontinued. 2 generic makers with 6 generic products listed as marketed; the first generic approval is dated 24 September 1986.

1980198519901995200020052010201520202025203002brand 1982Watson Laboratories Inc, first approval 1 October 1986Heritage Pharmaceuticals Inc Dba Avet Pharmaceuticals Inc, first approval 5 April 1988data date
generic makers listed as marketed, by first approvallisted patent expiryexclusivity end
Generic maker (applicant)First approvalProducts
Watson Laboratories Inc1 October 19863
Heritage Pharmaceuticals Inc Dba Avet Pharmaceuticals Inc5 April 19883

Patents and exclusivities still listed

No unexpired patent or exclusivity is listed against the marketed brand products in this group.

Tablet, Extended Release, Oral

Four or more generic makers listed

Every brand product here is listed as discontinued. 4 generic makers with 11 generic products listed as marketed; the first generic approval is dated 31 July 1992.

198519901995200020052010201520202025203004brand 1986Strides Pharma International Ag, first approval 25 May 1999Glenmark Pharmaceuticals Ltd, first approval 17 September 2009Cadila Pharmaceuticals Ltd, first approval 5 May 2017Zydus Lifesciences Global Fze, first approval 24 November 2025data date
generic makers listed as marketed, by first approvallisted patent expiryexclusivity end
Generic maker (applicant)First approvalProducts
Strides Pharma International Ag25 May 19992
Glenmark Pharmaceuticals Ltd17 September 20093
Cadila Pharmaceuticals Ltd5 May 20173
Zydus Lifesciences Global Fze24 November 20253

Patents and exclusivities still listed

No unexpired patent or exclusivity is listed against the marketed brand products in this group.

Injectable, Injection

Four or more generic makers listed

Every brand product here is listed as discontinued. 8 generic makers with 8 generic products listed as marketed; the first generic approval is dated 12 November 1985.

1980198519901995200020052010201520202025203008brand 1984Eugia Pharma Specialities Ltd, first approval 6 July 2020Gland Pharma Ltd, first approval 15 October 2020Zydus Pharmaceuticals Usa Inc, first approval 15 October 2020Heritage Pharmaceuticals Inc Dba Avet Pharmaceuticals Inc, first approval 17 March 2022Mankind Pharma Ltd, first approval 15 June 2022Fresenius Kabi Usa Llc, first approval 23 April 2024Aspiro Pharma Ltd, first approval 13 November 2025Knack Pharmaceuticals Inc, first approval 22 July 2026data date
generic makers listed as marketed, by first approvallisted patent expiryexclusivity end
Generic maker (applicant)First approvalProducts
Eugia Pharma Specialities Ltd6 July 20201
Gland Pharma Ltd15 October 20201
Zydus Pharmaceuticals Usa Inc15 October 20201
Heritage Pharmaceuticals Inc Dba Avet Pharmaceuticals Inc17 March 20221
Mankind Pharma Ltd15 June 20221
Fresenius Kabi Usa Llc23 April 20241
Aspiro Pharma Ltd13 November 20251
Knack Pharmaceuticals Inc22 July 20261

Patents and exclusivities still listed

No unexpired patent or exclusivity is listed against the marketed brand products in this group.

Solution, Intravenous

Four or more generic makers listed

Brand listed as marketed: Verapamil Hydrochloride. 5 generic makers with 13 generic products listed as marketed; the first generic approval is dated 6 May 1987.

1980198519901995200020052010201520202025203005brand 1984Hospira Inc, first approval 6 May 1987Somerset Therapeutics Llc, first approval 18 June 2018Micro Labs Ltd, first approval 28 December 2018Nephron Pharmaceuticals Corporation, first approval 17 March 2020Caplin Steriles Ltd, first approval 25 March 2020data date
generic makers listed as marketed, by first approvallisted patent expiryexclusivity end
Generic maker (applicant)First approvalProducts
Hospira Inc6 May 19873
Somerset Therapeutics Llc18 June 20184
Micro Labs Ltd28 December 20182
Nephron Pharmaceuticals Corporation17 March 20202
Caplin Steriles Ltd25 March 20202

Patents and exclusivities still listed

No unexpired patent or exclusivity is listed against the marketed brand products in this group.

Capsule, Extended Release, Oral

One to three generic makers listed

Brand listed as marketed: Verelan and Verelan Pm. 1 generic maker with 3 generic products listed as marketed; the first generic approval is dated 20 April 1999.

19901995200020052010201520202025203001brand 1990Mylan Pharmaceuticals Inc, first approval 20 April 1999data date
generic makers listed as marketed, by first approvallisted patent expiryexclusivity end
Generic maker (applicant)First approvalProducts
Mylan Pharmaceuticals Inc20 April 19993

Patents and exclusivities still listed

No unexpired patent or exclusivity is listed against the marketed brand products in this group.

US Food and Drug Administration, Orange Book data files, downloaded 12 November 2026. A listed patent is not a ruling that a generic is blocked, and no figure here says anything about price, supply or quality. Check the Orange Book.

What do pharmacies pay for Verapamil Hydrochloride?

The CMS NADAC survey tracks what pharmacies pay to acquire Verapamil Hydrochloride: 14 products with year-end prices from 2013 to 2026. See the acquisition cost history on RxGrab. It is a pharmacy cost, not a retail price, and this page does not say how it relates to the number of makers listed above.

Where can you go from this result?

Open it in the check to search another medicine, or see every brand with no generic listed. The FDA explains generic approval in how generic drugs are approved and the FDA generic drug facts, and the Orange Book itself is the FDA Orange Book. To check what is available now, ask your pharmacist, and see the FDA drug shortages page.